JP2018535951A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018535951A5 JP2018535951A5 JP2018519352A JP2018519352A JP2018535951A5 JP 2018535951 A5 JP2018535951 A5 JP 2018535951A5 JP 2018519352 A JP2018519352 A JP 2018519352A JP 2018519352 A JP2018519352 A JP 2018519352A JP 2018535951 A5 JP2018535951 A5 JP 2018535951A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- azacitidine
- amount
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 29
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical group O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims description 23
- 229960002756 azacitidine Drugs 0.000 claims description 23
- 229940125904 compound 1 Drugs 0.000 claims description 21
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 12
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 10
- 239000012650 DNA demethylating agent Substances 0.000 claims description 9
- 229940045805 DNA demethylating agent Drugs 0.000 claims description 9
- 239000002207 metabolite Substances 0.000 claims description 9
- 239000000651 prodrug Substances 0.000 claims description 9
- 229940002612 prodrug Drugs 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 239000012453 solvate Substances 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 9
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 6
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 6
- 108700028369 Alleles Proteins 0.000 claims description 6
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 6
- 206010066476 Haematological malignancy Diseases 0.000 claims description 4
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 4
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 4
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 3
- 208000016778 CD4+/CD56+ hematodermic neoplasm Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims description 3
- DYLUUSLLRIQKOE-UHFFFAOYSA-N enasidenib Chemical compound N=1C(C=2N=C(C=CC=2)C(F)(F)F)=NC(NCC(C)(O)C)=NC=1NC1=CC=NC(C(F)(F)F)=C1 DYLUUSLLRIQKOE-UHFFFAOYSA-N 0.000 claims description 3
- 102200116484 rs121913502 Human genes 0.000 claims description 3
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 claims 3
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 claims 3
- 238000011260 co-administration Methods 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 25
- 239000003112 inhibitor Substances 0.000 description 17
- 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 description 3
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 description 3
- 230000006872 improvement Effects 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562242218P | 2015-10-15 | 2015-10-15 | |
| US62/242,218 | 2015-10-15 | ||
| PCT/US2016/057102 WO2017066611A1 (en) | 2015-10-15 | 2016-10-14 | Combination therapy for treating malignancies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018535951A JP2018535951A (ja) | 2018-12-06 |
| JP2018535951A5 true JP2018535951A5 (enExample) | 2019-11-28 |
| JP6895956B2 JP6895956B2 (ja) | 2021-06-30 |
Family
ID=57219007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018519352A Active JP6895956B2 (ja) | 2015-10-15 | 2016-10-14 | 悪性腫瘍を治療するための併用療法 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10695352B2 (enExample) |
| EP (1) | EP3362070B1 (enExample) |
| JP (1) | JP6895956B2 (enExample) |
| KR (1) | KR102701893B1 (enExample) |
| CN (1) | CN108601787B (enExample) |
| AU (1) | AU2016340098B2 (enExample) |
| BR (1) | BR112018007447B1 (enExample) |
| CA (1) | CA3002029A1 (enExample) |
| CL (1) | CL2018000955A1 (enExample) |
| EA (1) | EA036129B1 (enExample) |
| ES (1) | ES2862730T3 (enExample) |
| IL (1) | IL258580B (enExample) |
| MX (1) | MX381582B (enExample) |
| SG (2) | SG11201802964QA (enExample) |
| WO (1) | WO2017066611A1 (enExample) |
| ZA (1) | ZA201802420B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9986928B2 (en) | 2013-12-09 | 2018-06-05 | Medtronic, Inc. | Noninvasive cardiac therapy evaluation |
| CA2942072C (en) | 2014-03-14 | 2022-07-26 | Agios Pharmaceuticals, Inc. | Pharmaceutical compositions and use of (s)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-( 4-cyanopyridin-2-yl)-n-( 5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide |
| IL258684B2 (en) | 2015-10-15 | 2023-04-01 | Agios Pharmaceuticals Inc | Combination therapy including an isocitrate dehydrogenase (1idh) inhibitor for use in the treatment of acute myelogenous leukemia (aml) characterized by the presence of a mutant allele of 1idh |
| RS62829B1 (sr) * | 2015-10-15 | 2022-02-28 | Servier Lab | Kombinovana terapija za lečenje maligniteta |
| US10905692B2 (en) | 2015-10-15 | 2021-02-02 | Agios Pharmaceuticals, Inc. | Combination therapy for treating malignancies |
| US11219769B2 (en) | 2016-02-26 | 2022-01-11 | Medtronic, Inc. | Noninvasive methods and systems of determining the extent of tissue capture from cardiac pacing |
| US11389454B2 (en) | 2016-09-07 | 2022-07-19 | Celgene Corporation | Tablet compositions |
| US11229653B2 (en) | 2017-05-05 | 2022-01-25 | Celgene Corporation | Methods of treatment of myeloproliferative neoplasm |
| BR112019026378A2 (pt) * | 2017-06-12 | 2020-07-21 | Agios Pharmaceuticals, Inc. | métodos de tratamento de tumores cerebrais usando terapia de combinação |
| JP7305613B2 (ja) * | 2017-07-09 | 2023-07-10 | バイオサイト リミテッド | 併用がん療法 |
| US11285312B2 (en) | 2018-03-29 | 2022-03-29 | Medtronic, Inc. | Left ventricular assist device adjustment and evaluation |
| US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
| US20220017490A1 (en) | 2018-11-02 | 2022-01-20 | Celgene Corporation | Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof |
| US12215094B2 (en) | 2018-11-02 | 2025-02-04 | Celgene Corporation | Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol |
| WO2020092915A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Solid dispersions for treatment of cancer |
| US11697025B2 (en) | 2019-03-29 | 2023-07-11 | Medtronic, Inc. | Cardiac conduction system capture |
| SG11202110702WA (en) * | 2019-04-29 | 2021-11-29 | Immunogen Inc | Therapeutic combinations comprising anti-cd123 immunoconjugates |
| BR112021025375A2 (pt) | 2019-06-20 | 2022-02-01 | Celgene Corp | Azacitidina em combinação com venetoclax, gilteritinibe, midostaurina ou outros compostos para tratamento de leucemia ou síndrome mielodisplástica |
| US11497431B2 (en) | 2019-10-09 | 2022-11-15 | Medtronic, Inc. | Systems and methods for configuring cardiac therapy |
| US12201843B2 (en) | 2019-10-09 | 2025-01-21 | Medtronic, Inc. | Synchronizing external electrical activity |
| JP2023503842A (ja) | 2019-11-14 | 2023-02-01 | セルジーン コーポレーション | がんを処置するための小児用製剤 |
| CN111087408B (zh) * | 2020-01-03 | 2021-04-02 | 浙江大学 | 一种大环结构的idh2突变体抑制剂及其医药用途 |
| US20240229156A1 (en) * | 2021-03-12 | 2024-07-11 | Celgene Corporation | Methods for using a hypomethylating agent to treat diseases and disorders based on gene mutation profiles |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| DE69831335T3 (de) | 1997-06-06 | 2015-01-15 | Depomed, Inc. | Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung |
| ATE340563T1 (de) | 2000-02-04 | 2006-10-15 | Depomed Inc | DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| US7038038B2 (en) * | 2003-03-17 | 2006-05-02 | Pharmion Corporation | Synthesis of 5-azacytidine |
| US6887855B2 (en) | 2003-03-17 | 2005-05-03 | Pharmion Corporation | Forms of 5-azacytidine |
| US6943249B2 (en) | 2003-03-17 | 2005-09-13 | Ash Stevens, Inc. | Methods for isolating crystalline Form I of 5-azacytidine |
| US7192781B2 (en) | 2004-04-13 | 2007-03-20 | Pharmion Corporation | Methods for stabilizing 5-azacytidine in plasma |
| MY161593A (en) * | 2008-05-15 | 2017-04-28 | Celgene Corp | Oral formulations of cytidine analogs and methods of use thereof |
| CA2725295C (en) * | 2008-06-09 | 2016-11-08 | Cyclacel Limited | Combination of sapacitabine (cndac) and dna methyltransferase inhibitors such as decitabine and procaine |
| JP6067226B2 (ja) | 2009-03-13 | 2017-01-25 | アジオス ファーマシューティカルズ， インコーポレイテッド | 細胞増殖関連疾患のための方法および組成物 |
| WO2011050211A2 (en) | 2009-10-21 | 2011-04-28 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
| KR101987861B1 (ko) * | 2011-11-03 | 2019-06-11 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | Nedd-8 활성화 효소 억제제 및 저메틸화제의 투여 |
| CA2860623A1 (en) | 2012-01-06 | 2013-07-11 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| SG11201600058XA (en) | 2013-07-11 | 2016-02-26 | Agios Pharmaceuticals Inc | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer |
| PE20160840A1 (es) | 2013-08-02 | 2016-09-22 | Agios Pharmaceuticals Inc | Formas cristalinas de compuestos inhibidores de isocitrato deshidrogenasa 2 (idh2) |
| WO2015018060A1 (en) | 2013-08-09 | 2015-02-12 | Agios Pharmaceuticals, Inc. | Crystalline forms of therapeutically active compounds and use thereof |
| KR20170057411A (ko) | 2014-09-29 | 2017-05-24 | 아지오스 파마슈티컬스 아이엔씨. | 치료적 활성 화합물 및 이들의 사용 방법 |
| KR102628370B1 (ko) | 2015-02-04 | 2024-01-24 | 르 라보레또레 쎄르비에르 | 치료적 활성 화합물 및 이들의 사용 방법 |
| AU2016303614A1 (en) | 2015-08-05 | 2018-02-15 | Agios Pharmaceuticals, Inc. | Methods of preparing 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diols and 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diamines |
| US10905692B2 (en) | 2015-10-15 | 2021-02-02 | Agios Pharmaceuticals, Inc. | Combination therapy for treating malignancies |
| MA43374A (fr) | 2015-12-04 | 2018-10-10 | Agios Pharmaceuticals Inc | Méthodes de traitement de tumeurs malignes |
| EP3419593B1 (en) | 2016-02-26 | 2022-03-23 | Celgene Corporation | Enasidenib for use in the treatment of relapsed or refractory acute myeloid leukaemia |
-
2016
- 2016-10-14 JP JP2018519352A patent/JP6895956B2/ja active Active
- 2016-10-14 EP EP16788866.8A patent/EP3362070B1/en active Active
- 2016-10-14 WO PCT/US2016/057102 patent/WO2017066611A1/en not_active Ceased
- 2016-10-14 ES ES16788866T patent/ES2862730T3/es active Active
- 2016-10-14 MX MX2018004599A patent/MX381582B/es unknown
- 2016-10-14 BR BR112018007447-0A patent/BR112018007447B1/pt active IP Right Grant
- 2016-10-14 KR KR1020187013741A patent/KR102701893B1/ko active Active
- 2016-10-14 SG SG11201802964QA patent/SG11201802964QA/en unknown
- 2016-10-14 SG SG10201912869WA patent/SG10201912869WA/en unknown
- 2016-10-14 CN CN201680072973.3A patent/CN108601787B/zh active Active
- 2016-10-14 US US15/768,462 patent/US10695352B2/en active Active
- 2016-10-14 EA EA201890961A patent/EA036129B1/ru not_active IP Right Cessation
- 2016-10-14 CA CA3002029A patent/CA3002029A1/en not_active Abandoned
- 2016-10-14 AU AU2016340098A patent/AU2016340098B2/en active Active
-
2018
- 2018-04-09 IL IL258580A patent/IL258580B/en active IP Right Grant
- 2018-04-12 ZA ZA2018/02420A patent/ZA201802420B/en unknown
- 2018-04-13 CL CL2018000955A patent/CL2018000955A1/es unknown
-
2020
- 2020-05-21 US US16/880,871 patent/US20210100805A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018535951A5 (enExample) | ||
| JP2019502669A5 (enExample) | ||
| JP2019513694A5 (enExample) | ||
| JP2021098740A5 (enExample) | ||
| JP2019510746A5 (enExample) | ||
| JP2018536636A5 (enExample) | ||
| JP2018534288A5 (enExample) | ||
| JP2019507721A5 (enExample) | ||
| JP2019142930A5 (enExample) | ||
| JP2017008088A5 (enExample) | ||
| JP2019216716A5 (enExample) | ||
| JP2017528487A5 (enExample) | ||
| JP2022166014A5 (enExample) | ||
| Gerber et al. | Management and future directions in non-small cell lung cancer with known activating mutations | |
| JP2020514311A5 (enExample) | ||
| IL278381B2 (en) | Methods for determining the effectiveness of a drug for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancer | |
| IL292608A (en) | Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | |
| JP2014513110A5 (enExample) | ||
| JP2006501176A5 (enExample) | ||
| JP2015508103A5 (enExample) | ||
| JP2013518089A5 (enExample) | ||
| JP2015511217A5 (enExample) | ||
| JP2015529194A5 (enExample) | ||
| JP2016503779A5 (enExample) | ||
| JP2010502767A5 (enExample) |